Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
Year: 2017
Type: review
Abstract: The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
Source: British Journal of Pharmacology
DOI: 10.1111/bph.13748
Authors: Nathan A Berger, Valerie C Besson, A Hamid Boulares, Alexander Bürkle, Alberto Chiarugi, Robert S Clark, Nicola J Curtin, Salvatore Cuzzocrea, Ted M Dawson, Valina L Dawson, György Haskó, Lucas Liaudet, Flavio Moroni, Pál Pacher, Peter Radermacher, Andrew L Salzman, Solomon H Snyder, Francisco Garcia Soriano, Robert P Strosznajder, Balázs Sümegi, Raymond A Swanson, Csaba Szabo
Institutions: Case Western Reserve University, Université Paris Cité, Sorbonne Paris Cité, Université Paris Descartes, Pharmacologie de la circulation cérébrale, Louisiana State University Health Sciences Center New Orleans, University of Konstanz, University of Florence, University of Pittsburgh, Newcastle University, University of Messina, Johns Hopkins University, Johns Hopkins Medicine, Rutgers New Jersey Medical School, Centre Hospitalier Universitaire Vaudois, University of Lausanne, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, University Hospital Ulm, Radikal Therapeutics, Universidade de São Paulo, Mossakowski Medical Research Institute, Polish Academy of Sciences, Polish Academy of Sciences, University of Pecs, San Francisco VA Medical Center, University of California, San Francisco, University of California San Francisco Medical Center, The University of Texas Medical Branch at Galveston
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Regulatory Control of Glutamate - Induced Superoxide Production, Drug Abuse Research Center, G1823348354, Modulation of the post-burn catabolic response by modification of androgen and glucocorticoid pathways, Parthanatos, AIF and PAAN-1 in Neuronal Injury, Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50), Mentoring in Cardiovascular Biology, Mentoring Translational Researchers in Louisiana
OpenAlex ID: W2612277616